Hereditary Angioedema: Clinical Trials

16 trials for Hereditary Angioedema, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 3 active not recruiting. 16 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 13, Active not recruiting 3
Phase 24Active not recruiting 3, Completed 1

Follow Hereditary Angioedema: new trials by email Literature Review of Hereditary Angioedema trials Research Report on Hereditary Angioedema

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema
Navenibart - Hereditary Angioedema
Phase 1 / Phase 2CompletedAstria Therapeutics, Inc.292023-02-212026-05-08
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
ADX-324, Placebo - Hereditary Angioedema
Phase 1 / Phase 2Active not recruitingADARx Pharmaceuticals, Inc.532022-12-142026-06-16
A Study of STAR-0215 in Healthy Adult Participants
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV) - Hereditary Angioedema
Phase 1CompletedAstria Therapeutics, Inc.412022-07-272024-01-11
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331 - Hereditary Angioedema, HAE
Phase 1 / Phase 2Active not recruitingBioMarin Pharmaceutical442022-02-152024-05-16
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Biological NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema
Phase 1 / Phase 2Active not recruitingIntellia Therapeutics372021-12-102026-09-25
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
KVD824 Prototype 1 modified-release tablet, KVD824 Prototype 2 modified-release tablet, KVD824 Immediate-Release Capsule - Hereditary Angioedema
Phase 1CompletedKalVista Pharmaceuticals, Ltd.372020-05-192021-11-12
Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers
GNR-038, 25 МЕ/kg, GNR-038, 50 МЕ/kg, GNR-038, 100 МЕ/kg - Hereditary Angioedema
Phase 1CompletedAO GENERIUM362020-03-102020-09-30
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
KVD824, Placebo to KVD824 - Hereditary Angioedema
Phase 1CompletedKalVista Pharmaceuticals, Ltd.1082019-02-122022-02-17
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers
KVD900, Placebo to KVD900 - Hereditary Angioedema
Phase 1CompletedKalVista Pharmaceuticals, Ltd.842018-01-042025-04-29
A Relative Bioavailability Study of Two Formulations of BCX7353
BCX7353 - Hereditary Angioedema
Phase 1CompletedBioCryst Pharmaceuticals242017-02-272020-01-27
A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
BCX7353, Digoxin, BCX7353 + digoxin - Hereditary Angioedema
Phase 1CompletedBioCryst Pharmaceuticals542017-02-172017-10-26
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
BCX7353 and probes - Hereditary Angioedema
Phase 1CompletedBioCryst Pharmaceuticals202016-03-012017-01-31
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
BCX7353, Placebo to match BCX7353 - Hereditary Angioedema
Phase 1CompletedBioCryst Pharmaceuticals1222015-05-012016-01-13
Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
BCX4161 - Hereditary Angioedema
Phase 1CompletedBioCryst Pharmaceuticals72014-08-012014-10-29
A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
BCX4161 - Hereditary Angioedema
Phase 1CompletedBioCryst Pharmaceuticals282014-04-012014-08-15
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
C1 esterase inhibitor [human] (C1INH-nf) - Hereditary Angioedema
Phase 1CompletedShire272006-10-092021-06-03

Narrower conditions

Angioedemas, Hereditary (16)  ·  Angioedema (3)  ·  Cardiovascular Diseases (1)  ·  Genetic Diseases, Inborn (1)  ·  Hypersensitivity (1)  ·  Hypersensitivity, Immediate (1)  ·  Immune System Diseases (1)  ·  Skin Diseases (1)  ·  Skin Diseases, Vascular (1)  ·  Urticaria (1)  ·  Vascular Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16)  ·  Hereditary Complement Deficiency Diseases (16)  ·  Immunologic Deficiency Syndromes (16)  ·  Primary Immunodeficiency Diseases (16)  ·  Skin and Connective Tissue Diseases (16)  ·  Cardiovascular Diseases (15)  ·  Genetic Diseases, Inborn (15)  ·  Hypersensitivity (15)  ·  Hypersensitivity, Immediate (15)  ·  Immune System Diseases (15)  ·  Skin Diseases (15)  ·  Skin Diseases, Vascular (15)  ·  Urticaria (15)  ·  Vascular Diseases (15)  ·  Angioedema (13)

Interventions

berotralstat (4)  ·  avoralstat (2)  ·  Complement C1 Inhibitor Protein (1)  ·  Cyclosporine (1)  ·  Digoxin (1)  ·  RNA, Small Interfering (1)  ·  Rosuvastatin Calcium (1)  ·  Sodium Chloride (1)  ·  sebetralstat (1)

Sponsors

BioCryst Pharmaceuticals (6)  ·  KalVista Pharmaceuticals, Ltd. (3)  ·  Astria Therapeutics, Inc. (2)  ·  ADARx Pharmaceuticals, Inc. (1)  ·  AO GENERIUM (1)  ·  BioMarin Pharmaceutical (1)  ·  Intellia Therapeutics (1)  ·  Shire (1)

Countries

United Kingdom (11)  ·  United States (4)  ·  Australia (3)  ·  Germany (2)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Netherlands (1)  ·  New Zealand (1)  ·  Russia (1)  ·  Spain (1)

Top investigators

Joanne Collier, MBChB, FFPM, Dip Stats (OU) (2)  ·  Firas Almazedi, MBChB, Msc, CPI (1)  ·  Joanne Collier (1)  ·  Lauge Farnaes, MD (1)  ·  Litza McKenzie, MBChB (1)  ·  Litza McKenzie, MBChB, BScMedSci (1)  ·  Oksana A. Markova, MD (1)

Results publications

PMID 35086692, PMID 38294975, PMID 39445704, PMID 40158724, PMID 41794053